- Home
- PBR vs ALNY Comparison
PBR vs ALNY Comparison
Compare PBR & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBR
- ALNY
- Stock Information
- Founded
- PBR 1953
- ALNY 2002
- Country
- PBR Brazil
- ALNY United States
- Employees
- PBR N/A
- ALNY N/A
- Industry
- PBR Oil & Gas Production
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- PBR Energy
- ALNY Health Care
- Exchange
- PBR Nasdaq
- ALNY Nasdaq
- Market Cap
- PBR 74.8B
- ALNY 60.7B
- IPO Year
- PBR N/A
- ALNY 2004
- Fundamental
- Price
- PBR $11.83
- ALNY $422.71
- Analyst Decision
- PBR Strong Buy
- ALNY Strong Buy
- Analyst Count
- PBR 3
- ALNY 26
- Target Price
- PBR $15.57
- ALNY $484.08
- AVG Volume (30 Days)
- PBR 25.5M
- ALNY 1.2M
- Earning Date
- PBR 11-06-2025
- ALNY 10-30-2025
- Dividend Yield
- PBR 14.25%
- ALNY N/A
- EPS Growth
- PBR N/A
- ALNY N/A
- EPS
- PBR 1.01
- ALNY 0.33
- Revenue
- PBR $85,533,373,883.00
- ALNY $3,210,070,000.00
- Revenue This Year
- PBR $534.45
- ALNY $65.55
- Revenue Next Year
- PBR $0.12
- ALNY $41.48
- P/E Ratio
- PBR $11.74
- ALNY $1,283.81
- Revenue Growth
- PBR N/A
- ALNY 53.24
- 52 Week Low
- PBR $11.03
- ALNY $205.87
- 52 Week High
- PBR $15.10
- ALNY $495.55
- Technical
- Relative Strength Index (RSI)
- PBR 45.22
- ALNY 34.48
- Support Level
- PBR $11.59
- ALNY $436.51
- Resistance Level
- PBR $12.05
- ALNY $485.36
- Average True Range (ATR)
- PBR 0.23
- ALNY 17.83
- MACD
- PBR 0.03
- ALNY -6.14
- Stochastic Oscillator
- PBR 57.48
- ALNY 1.20
About PBR Petroleo Brasileiro S.A.- Petrobras
Petrobras is a Brazil-based integrated energy company controlled by the Brazilian government. The company focuses on exploration and production of oil and gas in Brazilian offshore fields. Production in 2024 was 2.7 million barrels of oil equivalent a day (80% oil production), and reserves stood at 11.4 billion boe (85% oil). At end-2024, Petrobras operated 10 refineries in Brazil with capacity of 1.8 million barrels a day and distributes refined products and natural gas throughout Brazil.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.